Tilray's financial results were weaker than the top-line growth implied, and that's been the story for the better part of the last five years.
$6,000,000 ÷ 1,214,186 = $4.94 per share
With the the insider buying this week, it’s still important to note that % change in institutional shares held is down -49.15% from prior qtr to last qtr or -5,750,502 shares.
The cannabis sector is no stranger to volatility, but Tilray shareholders got a particularly jarring reminder of that reality on August 1, 2026. In a single trading session, two respected research houses delivered diametrically opposed verdicts on the stock: TD Securities upgraded the shares to "Strong Buy," while Wall Street Zen downgraded its rating to "Sell." The conflicting signals underscore just how fractured sentiment has become around the company's long-term profitability prospects.
The market likes when directors are buyers.
$249.64 X 4 =$998.56 in annualized revenues.
The NASDAQ is up roughly 2% today, yet Tilray is once again testing its 52-week low around $4.20 ahead of July 28 earnings. So what’s driving the disconnect?
$4.20 is the 52 week low. Think we will go lower before July 28? Tilray’s growth rate has been improving, but their bottom line has been soft. The acquisition costs have led to over $1 billion in losses the last two fiscal years. Will the narrative of strong top line growth through acquisition win or will the bottom line losses trend continue? Just avoiding a huge loss could be a catalyst for a bid. It would be really nice to see some confidence from management or institutions buying at the $4.20 range going into earnings, and that hasn’t happened yet.